1.Scoping review of pharmaceutical service provided by community pharmacists for patients with chronic diseases in China
Yuanhui HU ; Guolin LI ; Chang FENG ; Yuyao PEI ; Yufen ZHENG
China Pharmacy 2024;35(20):2559-2564
OBJECTIVE To summarize and analyze the profile of the implementation of pharmaceutical service by community pharmacists for patients with chronic diseases in China. METHODS Literature was searched from CNKI, Wanfang database, PubMed (Medline), Embase, and Scopus to collect studies about community pharmacists providing pharmaceutical services for patients with chronic diseases. The ways and contents of the implementation of pharmaceutical services for chronic diseases by community pharmacists were summarized descriptively. RESULTS A total of 75 studies were included, involving 49 trial studies and 26 cross-sectional studies. The study sites were mainly located in the developed regions of China, and the types of disease involved in the studies were mainly diabetes mellitus (n=30) and hypertension (n=28); most studies used the following indexes to evaluate pharmaceutical services, such as changes in disease symptoms and related indicators(n=35), improvement of patient compliance(n=34), and the occurrence of adverse drug reactions (irrational drug use) (n=25). The pharmaceutical service provided by community pharmacists included medication education (84.0%), monitoring and follow-up (64.0%), and identifying and solving medication-related problems (58.7%). Thirty-eight studies mentioned that pharmaceutical services were achieved through teamwork, 16 of which mentioned healthcare alliances. A few studies investigated stratified healthcare systems (n=15) and internet-based pharmaceutical services (n=10). CONCLUSIONS In China, pharmaceutical services provided by community pharmacies for patients with chronic diseases are still mainly confined to economically developed areas, and the scope of services is limited to a few diseases and basic pharmaceutical practices. In the future, the implementation of precise pharmaceutical services for different diseases and patients’ disease status, the establishment of medical alliances, and the development of internet-based pharmaceutical services should become the focus of pharmaceutical services.
2.Chinese Trauma Surgeon Association for management guidelines of vacuum sealing drainage application in abdominal surgeries-Update and systematic review.
Yang LI ; Pei-Yuan LI ; Shi-Jing SUN ; Yuan-Zhang YAO ; Zhan-Fei LI ; Tao LIU ; Fan YANG ; Lian-Yang ZHANG ; Xiang-Jun BAI ; Jing-Shan HUO ; Wu-Bing HE ; Jun OUYANG ; Lei PENG ; Ping HU ; Yan-An ZHU ; Ping JIN ; Qi-Feng SHAO ; Yan-Feng WANG ; Rui-Wu DAI ; Pei-Yang HU ; Hai-Ming CHEN ; Ge-Fei WANG ; Yong-Gao WANG ; Hong-Xu JIN ; Chang-Ju ZHU ; Qi-Yong ZHANG ; Biao SHAO ; Xi-Guang SANG ; Chang-Lin YIN
Chinese Journal of Traumatology 2019;22(1):1-11
Vacuum sealing drainage (VSD) is frequently used in abdominal surgeries. However, relevant guidelines are rare. Chinese Trauma Surgeon Association organized a committee composed of 28 experts across China in July 2017, aiming to provide an evidence-based recommendation for the application of VSD in abdominal surgeries. Eleven questions regarding the use of VSD in abdominal surgeries were addressed: (1) which type of materials should be respectively chosen for the intraperitoneal cavity, retroperitoneal cavity and superficial incisions? (2) Can VSD be preventively used for a high-risk abdominal incision with primary suture? (3) Can VSD be used in severely contaminated/infected abdominal surgical sites? (4) Can VSD be used for temporary abdominal cavity closure under some special conditions such as severe abdominal trauma, infection, liver transplantation and intra-abdominal volume increment in abdominal compartment syndrome? (5) Can VSD be used in abdominal organ inflammation, injury, or postoperative drainage? (6) Can VSD be used in the treatment of intestinal fistula and pancreatic fistula? (7) Can VSD be used in the treatment of intra-abdominal and extra-peritoneal abscess? (8) Can VSD be used in the treatment of abdominal wall wounds, wound cavity, and defects? (9) Does VSD increase the risk of bleeding? (10) Does VSD increase the risk of intestinal wall injury? (11) Does VSD increase the risk of peritoneal adhesion? Focusing on these questions, evidence-based recommendations were given accordingly. VSD was strongly recommended regarding the questions 2-4. Weak recommendations were made regarding questions 1 and 5-11. Proper use of VSD in abdominal surgeries can lower the risk of infection in abdominal incisions with primary suture, treat severely contaminated/infected surgical sites and facilitate temporary abdominal cavity closure.
Abdomen
;
surgery
;
China
;
Drainage
;
methods
;
Evidence-Based Medicine
;
Humans
;
Practice Guidelines as Topic
;
Societies, Medical
;
organization & administration
;
Surgical Wound Infection
;
prevention & control
;
Traumatology
;
organization & administration
;
Vacuum